Gemtuzumab Ozogamicin represents a significant advance in the treatment of relapsed leukemic disease, mainly aggressive myeloid leukemia (AML). This agent pairs a targeted immunoglobulin directed at the target marker https://www.targetmol.com/compound/gemtuzumab